Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00219-7 ◽

2011 ◽

Vol 2011 ◽

pp. 171-172 ◽

Author(s):

J.T. Thigpen

Keyword(s):

Prostate Cancer ◽

Multiple Myeloma ◽

Zoledronic Acid ◽

Bone Metastases ◽

Advanced Cancer ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Breast And Prostate Cancer

Download Full-text

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.021 ◽

2011 ◽

Vol 2011 ◽

pp. 1-2 ◽

Author(s):

J.T. Thigpen

Keyword(s):

Prostate Cancer ◽

Multiple Myeloma ◽

Zoledronic Acid ◽

Bone Metastases ◽

Advanced Cancer ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Breast And Prostate Cancer

Download Full-text

20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)72055-5 ◽

2009 ◽

Vol 7 (3) ◽

pp. 12 ◽

Author(s):

D. Henry ◽

R. von Moos ◽

S. Vadhan-Raj ◽

V. Hungria ◽

A. Spencer ◽

...

Keyword(s):

Prostate Cancer ◽

Multiple Myeloma ◽

Zoledronic Acid ◽

Bone Metastases ◽

Advanced Cancer ◽

Randomized Study ◽

Double Blind ◽

Breast And Prostate Cancer

Download Full-text

Faculty Opinions recommendation of Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9875966.793494170 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study

Yearbook of Urology ◽

10.1016/j.yuro.2011.06.011 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

A.S. Kibel

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Re: Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Men With Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study

The Journal of Urology ◽

10.1016/j.juro.2011.08.108 ◽

2011 ◽

Vol 186 (6) ◽

pp. 2254-2255 ◽

Author(s):

Patrick C. Walsh

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

10.1016/s0140-6736(10)62344-6 ◽

2011 ◽

Vol 377 (9768) ◽

pp. 813-822 ◽

Cited By ~ 1203

Author(s):

Karim Fizazi ◽

Michael Carducci ◽

Matthew Smith ◽

Ronaldo Damião ◽

Janet Brown ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9875966.793514277 ◽

2016 ◽

Author(s):

Badrinath Konety

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9875966.10590066 ◽

2011 ◽

Author(s):

James Catto ◽

Kate Linton

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958301.793464607 ◽

2012 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Download Full-text

Faculty Opinions recommendation of Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.7216956.8792054 ◽

2011 ◽

Author(s):

Carmelo Bengala

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Download Full-text